Cell News and Research

RSS

Soon a single therapy for range of brain diseases like Parkinson’s and Alzheimer’s

In a study, published in Nature, researchers prevented brain cells dying in mice with prion disease. It is hoped the same method for preventing brain cell death could apply in other diseases. The findings are at an early stage, but have been heralded as “fascinating”.

8 May 2012

Mini-Lecture Series from ARUP Laboratories

ARUP Laboratories, a national reference laboratory, is pleased to announce its Mini-Lecture Series during the annual Scientific Meeting of the American Pain Society in Honolulu.

8 May 2012

Campaign announces search for Arizona teens to participate in Addicteen

Arizona's anti-smoking youth campaign, Venomocity Brought to You by Addiction announces a search for Arizona teens to participate in Addicteen, a documentary about addiction. The film will examine activities which teenagers have defined as being addictive including, texting, social media and the use of tobacco. Filmmakers seek to draw out the similarities, differences and impacts of these behaviors on the lives of today's youth.

8 May 2012

T2M cells play a crucial role in treatment-resistant asthma

For most people with asthma, a couple of puffs from an inhaler filled with steroids makes breathing easy. But if their lungs become resistant to the calming effect of that medicine, they live in fear of severe asthma attacks that could send them to the hospital - or worse. Now, new research from the University of Michigan Health System may help explain what's going on in the lungs of these steroid-resistant individuals. The findings could aid the development of new treatment options, and of better ways to identify people at risk of becoming steroid-resistant.

8 May 2012

Researchers discover CD19 pathway that leads to lymphoma

Researchers studying the molecular signals that drive a specific type of lymphoma have discovered a key biological pathway leading to this type of cancer. Cancerous cells have been described as being "addicted" to certain oncogenes (cancer-causing genes), and the new research may lay the groundwork for breaking that addiction and effectively treating aggressive types of B cell lymphoma.

8 May 2012

Zinc oxide could increase risk of skin cancer

As vacationers prepare to spend time outdoors this summer, many of them will pack plenty of sunscreen in hopes it will protect their bodies from overexposure, and possibly from skin cancer. But researchers at Missouri University of Science and Technology are discovering that sunscreen may not be so safe after all.

8 May 2012

Affymax first quarter total revenue increases to $63.2 million

Affymax, Inc. today reported financial results for the first quarter ended March 31, 2012. The net income for the first quarter of 2012 was $31.5 million (or $0.87 per share) compared to a net loss of $9.6 million (or $(0.36) per share) for the first quarter of 2011.

8 May 2012

Healthy newborns should not be over-protected against natural exposure of gut flora

Infants whose gut is colonised by E. coli bacteria early in life have a higher number of memory B cells in their blood, reveals a study of infants carried out at the Sahlgrenska Academy at the University of Gothenburg, Sweden.

7 May 2012

Intellect Neurosciences announces two new programs in Alzheimer's disease development pipeline

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.

7 May 2012

Vertex reports interim data from VX-809 and KALYDECO combination Phase 2 study for cystic fibrosis

Vertex Pharmaceuticals Incorporated announced today an interim analysis of data from an ongoing Phase 2 study of VX-809 and KALYDECO (ivacaftor) that showed significant improvements in lung function (FEV1) among adults with cystic fibrosis (CF) who have two copies.

7 May 2012

TOKU-E introduces faster dissolving dust-free grade Sodium Dodecyl Sulfate

TOKU-E Company has announced availability of their newly developed, innovative, ultra-safe, faster dissolving dust-free grade (DF) Sodium Dodecyl Sulfate (SDS).

7 May 2012

Latest science from area of network biology

This week experts from around the world will meet to discuss how network models can be applied to the study and targeting of complex diseases such as cancer, diabetes and neurological disorders.

7 May 2012

NovaDigm reports positive data from Phase 1 NDV-3 vaccine program

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the presentation of positive data for its NDV-3 vaccine program in a second Phase 1 study.

7 May 2012

Data from Idera IMO-8400 preclinical studies for SLE and psoriasis presented at AAI meeting

Idera Pharmaceuticals, Inc. today announced data from preclinical studies of IMO-8400, demonstrating a novel mechanism of action that may be applicable to the treatment of systemic lupus erythematosus (SLE) and psoriasis. IMO-8400 is an inhibitor of specific Toll-like receptors (TLRs).

7 May 2012

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone).

7 May 2012

ADVENTRX first quarter net loss increases to $4.2M

ADVENTRX Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2012.

7 May 2012

KYTHERA ATX-101-10-16 trial for submental fat meets primary endpoints

KYTHERA Biopharmaceuticals, Inc. today announced the presentation of initial trial results from Study ATX-101-10-16, the first of two pivotal European Phase III clinical trials with ATX-101, a facial injectable drug for the reduction of unwanted fat under the chin, or submental fat.

7 May 2012

CNV in prostate cancer tumors may accurately predict relapse

While active monitoring of serum prostate specific antigen (PSA) levels in men over 50 has greatly improved early detection of prostate cancer, prediction of clinical outcomes after diagnosis remains a major challenge.

7 May 2012

Researchers discover how diabetes affects specific brain area leading to memory loss

Badly controlled diabetes are known to affect the brain causing memory and learning problems and even an increased incidence of dementia, although how this occurs is not clear.

7 May 2012

Automated way to record electrical activity inside neurons in the living brain

Gaining access to the inner workings of a neuron in the living brain offers a wealth of useful information: its patterns of electrical activity, its shape, even a profile of which genes are turned on at a given moment. However, achieving this entry is such a painstaking task that it is considered an art form; it is so difficult to learn that only a small number of labs in the world practice it.

7 May 2012